X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-06-24 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale | $2.12 | -6,849 | 10,869 | -39% | -$14,520 | ||||||
D | 2024-05-29 | GNLX | Yu Yong | VP, Clinical Trial Operations | P - Purchase | $0.00 | +2,500 | 2,500 | New | +$0 | |||||
2023-12-15 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale | $13.16 | -32,535 | 0 | -100% | -$428,180 | ||||||
2023-12-07 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale | $11.85 | -36,800 | 32,535 | -53% | -$435,995 | ||||||
2023-11-21 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale | $10.26 | -18,665 | 69,335 | -21% | -$191,555 | ||||||
D | 2023-10-24 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale+OE | $19.11 | -5,200 | 106,135 | -5% | -$99,351 | |||||
D | 2023-10-10 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale+OE | $22.01 | -5,200 | 106,135 | -5% | -$114,462 | |||||
D | 2023-09-26 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale+OE | $23.56 | -5,200 | 106,135 | -5% | -$122,528 | |||||
D | 2023-09-20 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale+OE | $27.96 | -6,000 | 106,135 | -5% | -$167,786 | |||||
D | 2023-09-15 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale+OE | $21.89 | -10,400 | 106,135 | -9% | -$227,630 | |||||
2023-09-13 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale | $21.14 | -29,800 | 106,135 | -22% | -$629,927 | ||||||
2023-08-30 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale | $24.70 | -19,800 | 135,935 | -13% | -$489,060 | ||||||
2023-08-18 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale | $23.73 | -3,265 | 155,735 | -2% | -$77,478 |
A | Amended filing |
D | Derivative transaction in filing (usually option exercise) |
E | Error detected in filing |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |